Physician

Paul V Lacava, M.D.

According to 2025 Medicare claims, Paul Lacava, M.D. (NPI: 1942399365) practices internal medicine in the Trenton-Princeton, NJ market, with the plurality of this provider's patient population coming from Mercer, NJ. This provider's primary affiliated billing organization is PRINCETON MEDICAL GROUP,P.A. (NPI: 1063513679; TIN: 222306123) and primary practice location at 08540-3594. Lacava is affiliated with the Aledade 25 NJ MSSP Enhanced (ACO ID: A3891), participating under the MSSP model.

Lacava's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 677 traditional Medicare patients, billed 7,854 HCPCS/CPT codes, and received $274,895 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 8,338 prescription claims across 926 beneficiaries totaling $508,634 in drug costs, led by Eliquis (Apixaban). DME data shows 22 claims. Open Payments data shows 2 records totaling $32. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,108 and ending at $1,422.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	591	6,902	$254,141
2016	624	6,580	$212,318
2017	610	6,712	$215,080
2018	670	7,343	$236,362
2019	615	7,058	$220,593
2020	642	6,946	$207,650
2021	631	7,063	$246,804
2022	718	7,056	$263,268
2023	678	7,415	$272,083
2024	677	7,854	$274,895

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	690	6,009	$522,699
2016	703	5,947	$538,132
2017	726	6,296	$501,397
2018	781	6,741	$467,220
2019	812	6,902	$504,166
2020	826	7,375	$546,229
2021	837	7,491	$546,814
2022	914	8,133	$591,345
2023	921	8,224	$559,141
2024	926	8,338	$508,634

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	15	40	$494
2016	31	86	$1,936
2017	16	65	$696
2018	15	75	$838
2019	N/R	30	$303
2020	N/R	29	$328
2021	N/R	12	$124
2022	N/R	11	$330
2023	N/R	N/R	N/R
2024	N/R	22	$2,584

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	528	528	$137
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	577	665	$60
84443	Blood test, thyroid stimulating hormone (tsh)	453	533	$16
80053	Blood test, comprehensive group of blood chemicals	474	692	$10
36415	Insertion of needle into vein for collection of blood sample	528	831	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	85	5,120	$95,600
Jardiance	Empagliflozin	39	3,030	$57,810
Farxiga	Dapagliflozin Propanediol	15	1,290	$22,885
Januvia	Sitagliptin Phosphate	12	1,020	$17,437
Entresto	Sacubitril/Valsartan	15	690	$14,852

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4407	Ostomy skin barrier, with flange (solid, flexible, or accordion), extended wear, with built-in convexity, 4 x 4 inches or smaller, each	N	N/R	11	$1,780
A4425	Ostomy pouch, drainable; for use on barrier with non-locking flange, with filter (2 piece system), each	N	N/R	11	$803

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$32	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul V. Lacava, M.D.?

Tedicare shows public-source Medicare data for Paul V. Lacava, M.D. (NPI 1942399365), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul V. Lacava, M.D. have ACO affiliation data?

Paul V. Lacava, M.D. is shown with ACO affiliation data for Aledade 25 NJ MSSP Enhanced (MSSP, ACO ID A3891).

What billing organization is linked to Paul V. Lacava, M.D.?

Paul V. Lacava, M.D. is linked to PRINCETON MEDICAL GROUP,P.A. (billing NPI 1063513679) in the available physician profile data.

Does Paul V. Lacava, M.D. have Open Payments data?

Paul V. Lacava, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.